Chronically implantable, closed-loop neuromodulation devices with concurrent sensing and stimulation hold promise for better understanding the nervous system and improving therapies for neurological disease. Concurrent sensing and stimulation are needed to maximize usable neural data, minimize time delays for closed-loop actuation, and investigate the instantaneous response to stimulation. Current systems lack concurrent sensing and stimulation primarily because of stimulation interference to neural signals of interest. While careful design of high performance amplifiers has proved useful to reduce disturbances in the system, stimulation continues to contaminate neural sensing due to biological effects like tissue-electrode impedance mismatch and constraints on stimulation parameters needed to deliver therapy. In this work we describe systematic methods to mitigate the effect of stimulation through a combination of sensing hardware, stimulation parameter selection, and classification algorithms that counter residual stimulation disturbances. To validate these methods we implemented and tested a completely implantable system for over one year in a large animal model of epilepsy. The system proved capable of measuring and detecting seizure activity in the hippocampus both during and after stimulation. Furthermore, we demonstrate an embedded algorithm that actuates neural modulation in response to seizure detection during stimulation, validating the capability to detect bioelectrical markers in the presence of therapy and titrate it appropriately. The capability to detect neural states in the presence of stimulation and optimally titrate therapy is a key innovation required for generalizing closed-loop neural systems for multiple disease states.
7 November 2018 in IEEE Transactions on Biomedical Circuits and Systems
Developing new tools to better understand disorders of the nervous system, with a goal to more effectively treat them, is an active area of bioelectronic medicine research. Future tools must be flexible and configurable, given the evolving understanding of both neuromodulation mechanisms and how to configure a system for optimal clinical outcomes. We describe a system, the Summit RC+S "neural coprocessor," that attempts to bring the capability and flexibility of a microprocessor to a prosthesis embedded within the nervous system. This paper describes the updated system architecture for the Summit RC+S system, the five custom integrated circuits required for bi-directional neural interfacing, the supporting firmware/software ecosystem, and the verification and validation activities to prepare for human implantation. Emphasis is placed on design changes motivated by experience with the CE-marked Activa PC+S research tool; specifically, enhancement of sense-stim performance for improved bi-directional communication to the nervous system, implementation of rechargeable technology to extend device longevity, and application of MICS-band telemetry for algorithm development and data management. The technology was validated in a chronic treatment paradigm for canines with naturally occurring epilepsy, including free ambulation in the home environment, which represents a typical use case for future human protocols.
Adaptive deep brain stimulation (aDBS) is an emerging advancement in DBS technology; however, local field potential (LFP) signal rate detection sufficient for aDBS algorithms and the methods to set-up aDBS have yet to be defined. Here we summarize sensing data and aDBS programming steps associated with the ongoing Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) pivotal trial (NCT04547712). Sixty-eight patients were enrolled with either subthalamic nucleus or globus pallidus internus DBS leads connected to a Medtronic PerceptTM PC neurostimulator. During the enrollment and screening procedures, a LFP (8–30 Hz, ≥1.2 µVp) control signal was identified by clinicians in 84.8% of patients on medication (65% bilateral signal), and in 92% of patients off medication (78% bilateral signal). The ADAPT-PD trial sensing data indicate a high LFP signal presence in both on and off medication states of these patients, with bilateral signal in the majority, regardless of PD phenotype.
Background: In prior reports, we described the design and initial performance of a fully implantable, bi-directional neural interface system for use in deep brain and other neurostimulation applications. Here we provide an update on the chronic, long-term neural sensing performance of the system using traditional 4-contact leads and extend those results to include directional 8-contact leads.Methods: Seven ovine subjects were implanted with deep brain stimulation (DBS) leads at different nodes within the Circuit of Papez: four with unilateral leads in the anterior nucleus of the thalamus and hippocampus; two with bilateral fornix leads, and one with bilateral hippocampal leads. The leads were connected to either an Activa PC+S® (Medtronic) or Percept PC°ledR (Medtronic) deep brain stimulation and recording device. Spontaneous local field potentials (LFPs), evoked potentials (EPs), LFP response to stimulation, and electrode impedances were monitored chronically for periods of up to five years in these subjects.Results: The morphology, amplitude, and latencies of chronic hippocampal EPs evoked by thalamic stimulation remained stable over the duration of the study. Similarly, LFPs showed consistent spectral peaks with expected variation in absolute magnitude dependent upon behavioral state and other factors, but no systematic degradation of signal quality over time. Electrode impedances remained within expected ranges with little variation following an initial stabilization period. Coupled neural activity between the two nodes within the Papez circuit could be observed in synchronized recordings up to 5 years post-implant. The magnitude of passive LFP power recorded from directional electrode segments was indicative of the contacts that produced the greatest stimulation-induced changes in LFP power within the Papez network.Conclusion: The implanted device performed as designed, providing the ability to chronically stimulate and record neural activity within this network for up to 5 years of follow-up.
Deep brain stimulation (DBS) of the fornix (FX) is being explored as a therapy for memory impairment in Alzheimer's disease, but clinical trials have yielded mixed results. The physiological mechanisms underlying these outcomes, particularly the state-dependent dynamics of fornix-hippocampal (HC) communication, remain poorly understood. To dissect the state-dependent dynamics of FX-HC communication and assess the impact of continuous DBS using chronic local field potential (LFP) recordings, spectral analysis, machine learning, and advanced causal inference techniques. Three ovine subjects were implanted with DBS leads targeting the FX and HC. Chronic LFP recordings were obtained during awake and overnight periods, with and without stimulation. Spectral analysis identified theta band (4-8 Hz) as the frequency of interest. Unsupervised k-means clustering and linear discriminant analysis classified high-theta and low-theta states. This state definition was used to differentiate state-dependent dynamics in communication between the fornix and hippocampus. Granger causality and causal discovery methods quantified the directionality and strength of FX-HC interactions. Bidirectional, state-dependent communication was observed: during high-theta states HC→FX drive was dominant over FX- > HC, while in low-theta states FX→HC drive was enhanced over high-theta states. Continuous FX stimulation disrupted this balance, overdriving FX→HC connectivity and attenuating HC→FX feedback, effectively creating an "electrical lesion." Causal discovery analyses corroborate these findings. Continuous fornix DBS disrupts physiological bidirectional communication within the FX-HC network, which may underlie the limited efficacy seen in clinical trials. These results highlight the need for adaptive or cycled stimulation paradigms to preserve endogenous network function and optimize therapeutic outcomes.